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Use of the English urgent referral pathway for suspected cancer 
and mortality in patients with cancer: cohort study
Henrik Møller,1,5 Carolynn Gildea,2 David Meechan,2 Greg Rubin,3 Thomas Round,4 Peter Vedsted5 
ABSTRACT
ObjeCtive
To assess the overall effect of the English urgent 
referral pathway on cancer survival.
Setting
8049 general practices in England.
DeSign
Cohort study. Linked information from the national 
Cancer Waiting Times database, NHS Exeter database, 
and National Cancer Register was used to estimate 
mortality in patients in relation to the propensity of their 
general practice to use the urgent referral pathway.
PartiCiPantS
215 284 patients with cancer, diagnosed or first treated 
in England in 2009 and followed up to 2013. 
OutCOme meaSure
 Hazard ratios for death from any cause, as estimated 
from a Cox proportional hazards regression.
reSultS
During four years of follow-up, 91 620 deaths occurred, of 
which 51 606 (56%) occurred within the first year after 
diagnosis. Two measures of the propensity to use urgent 
referral, the standardised referral ratio and the detection 
rate, were associated with reduced mortality. The hazard 
ratio for the combination of high referral ratio and high 
detection rate was 0.96 (95% confidence interval 0.94 to 
0.99), applying to 16% (n=34 758) of the study 
population. Patients with cancer who were registered 
with general practices with the lowest use of urgent 
referral had an excess mortality (hazard ratio 1.07 (95% 
confidence interval 1.05 to 1.08); 37% (n=79 416) of the 
study population). The comparator group for these two 
hazard ratios was the remaining 47% (n=101 110) of the 
study population. This result in mortality was consistent 
for different types of cancer (apart from breast cancer) 
and with other stratifications of the dataset, and was not 
sensitive to adjustment for potential confounders and 
other details of the statistical model.
COnCluSiOnS
Use of the urgent referral pathway could be efficacious. 
General practices that consistently have a low 
propensity to use urgent referrals could consider 
increasing the use of this pathway to improve the 
survival of their patients with cancer.
Introduction
Achieving an earlier diagnosis of cancer at a less 
advanced stage is a public concern and has become a 
widely adopted priority for healthcare systems. It is 
generally assumed that the more promptly a diagnosis 
of cancer is made, the better is the prognosis, because 
cancer detected at an earlier stage has better treatment 
options leading to improved survival.1 This assumption 
is supported by evidence that tumours can progress 
during the time taken to reach a diagnosis and start 
treatment.2 3  Observational studies have found an asso-
ciation between time to diagnosis and mortality.4-7
The time for a patient to reach a diagnosis of cancer 
can be influenced by patient, practitioner, and health-
care system delays.8  Several countries where general 
practitioners have a gatekeeping role for access to spe-
cialist care have introduced (or are introducing) urgent 
referral pathways for patients with symptoms sugges-
tive of cancer.9-11 Typically, such pathways enable rapid 
access to a specialist opinion or diagnostic test (within 
two weeks in England) for patients with specified alarm 
symptoms, such as abnormal bleeding, unexplained 
weight loss, or an unexplained lump or abdominal 
mass. These pathways are supported by clinical guide-
lines for their use. 
The current pathway in England12  was revised in June 
2015. For some cancers, evidence now suggests that use 
of the pathway is associated with a shorter time to diag-
nosis and treatment, although the size of the effect varies 
by cancer site.8 13- 18  For colorectal cancer, in one report 
from a Spanish research group, time to diagnosis after 
urgent referral was 19 days less than by routine referral.16 
However, there is not yet evidence indicating that this 
diagnostic strategy has an effect on the overall prognosis 
and mortality of patients with cancer in the population.
In the United Kingdom, the frequency with which 
general practices use the urgent referral pathway for 
suspected cancer and the accuracy of their patient 
selection for urgent referral varies considerably.19-21 
This variation provides an opportunity to explore and 
quantify the association between use of urgent referral 
and cancer outcomes. We assessed the association 
between the propensity of general practices to use 
urgent referral and the precision of its use, and the 
overall mortality among their patients with cancer.
Methods
Our analysis used a dataset of urgent referrals and can-
cer diagnoses constructed by Meechan and colleagues20 
from the English national Cancer Waiting Times22 
WhAT IS AlReAdy knoWn on ThIS TopIC
The urgent referral pathway for patients with suspected cancer has been available 
in England since the early 2000s, but its impact on cancer survival is unknown
WhAT The pApeR AddS
We analysed survival of 215 284 patients with cancer in England, in relation to their 
general practice’s propensity to use urgent referral
The propensity to use the urgent referral pathway was associated with reduced mortality 
General practices that consistently have a low propensity to use urgent referrals 
could consider increasing their use of this pathway, thereby plausibly increasing 
the survival of their patients with cancer
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 database, where information was collected from trusts 
in the UK’s health service for official monitoring of the 
Cancer Waiting Times standards. This dataset, of 
patients with a date of a first hospital appointment or 
treatment in 2009, contained records of 865 494 urgent 
referrals for suspected cancer and 224 984 diagnosed 
cancers from 8049 general practices; 43% of the can-
cers were diagnosed following urgent referral. To asso-
ciate each patient with a general practice, these records 
were linked by NHS number, through the open Exeter 
portal tracing service, to the NHS Exeter database.23 
The NHS Exeter database contains registration details 
for all patients registered with an NHS general practi-
tioner in England and Wales; Cancer Waiting Times 
records that were not linked here were not included in 
the Meechan and colleagues’20 dataset.
For verification of the cancer diagnosis and survival 
follow-up, the records were also linked with the 
National Cancer Register24-26 by NHS number, date of 
diagnosis, and cancer type. We excluded from all anal-
yses the small proportion of patients for whom there 
was no verified diagnosis.
We also excluded practices with a very small list size 
or a large change in list size.20 All patients in the study 
had non-missing values for all variables, except 141 
patients who had missing data for socioeconomic sta-
tus. In the sensitivity analysis with adjustment for 
socioeconomic status, these 141 patients were included 
as a separate group.
We used three referral metrics:
•	 Practice referral ratio: the indirectly standardised 
number of urgent referrals for suspected cancer by 
general practitioners, standardised according to the 
general practice’s list size and to the age and sex dis-
tributions of people on the list. This number was 
computed by the ratio of the observed number of 
referrals to the expected number of referrals (with 
the expected number calculated from age and sex 
specific list size data for each general practice, and 
from national age and sex specific rates of urgent 
referral)
•	 Practice conversion rate: the proportion of urgent 
referrals for suspected cancer by general practi-
tioners that result in a diagnosis of cancer. This is the 
positive predictive value for cancer among the 
patients selected for urgent referral
•	 Practice detection rate: the proportion of Cancer 
Waiting Times recorded cancers resulting from an 
urgent referral for suspected cancer by general prac-
titioners. This is the sensitivity of the selection of 
patients for urgent referral in the general practice.
We used Cox proportional hazards regression to analyse 
and quantify the hazard of death from any cause in 
 relation to referral ratio, conversion rate, and detection 
rate; we assessed these measures individually, condi-
tionally (mutually adjusted), and with stratification by 
combinations. All analyses were adjusted for age (linear 
and second order terms) and sex (binary) of the individual 
patient, as well as for the main types of cancer (colorec-
tal, lung, breast, prostate, other) as a categorical vari-
able. The main analysis used the four year time window 
of follow-up from diagnosis to death, censoring at four 
years or at the study end date in December 2013, which-
ever occurred first.
We used Schoenfeld residuals to explore the assump-
tion of proportional hazards. The assumption was gen-
erally upheld, but there were some differences between 
the main types of cancer (web appendix B-G).
Referral ratio, conversion rate, and detection rate 
were analysed as categorical variables, according to 
groups divided by tertiles of their distributions (that is, 
divided into three equal groups). Analysis by categori-
cal variables was decided a priori because we expected 
that associations might be non-linear, and in order to 
facilitate analysis of the joint effects of the variables.
We pursued various stratified analyses and sensitiv-
ity analyses to improve the consistency and internal 
validity of the findings. The main analysis used a four 
year follow-up, and we also explored shorter durations 
of follow-up by censoring at one or two years after diag-
nosis. We checked the sensitivity of the principal find-
ings in the subset of patients for whom diagnosis and 
date of diagnosis were consistent with the National 
Cancer Register (that is, identical ICD-10 diagnosis 
codes at the three digit level, and dates of diagnosis 
within 90 days of each other). 
We analysed the data for each of the most frequent 
types of cancer separately, and evaluated whether the 
overall results changed if no adjustment was made for 
cancer type. In separate analyses, we adjusted for the 
patient’s socioeconomic status or for the age and sex 
distribution of the general practice’s list population. 
For socioeconomic status, we used groups based on 
quintiles of the income domain of the index of multiple 
deprivation as a categorical variable (that is, divided 
into five equal groups). For age and sex distribution, we 
used groups based on tertiles of the median age of 
patients from each practice as a categorical variable 
(that is, divided into three equal groups), and the pro-
portion of male patients on the list as a continuous vari-
able. We used a shared frailty random effects model27  to 
accommodate the multilevel structure of data where 
groups of patients with cancer belong to the same gen-
eral practice list. All analyses were carried out with 
Stata version 12.28
Patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved in 
the design and implementation of the study. Study 
results and implications were discussed with patients 
with cancer, carers and lay people at meetings, work-
shops and conferences. The work on cancer diagnostics 
in King’s College London is overseen by a patient and 
public involvement steering group.
Results
The cohort of patients with cancer for analysis, after 
elimination of multiple records (5276 records) and 
patients for whom there was no verified diagnosis in the 
National Cancer Register (4374 patients), comprised 
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215 284 patients with cancer (fig 1). During four years of 
follow-up, 91 620 deaths occurred, of which 51 606 
(56%) occurred within the first year after diagnosis.
Figure 2  shows the distributions of referral ratio, con-
version rate, and detection rate. The three measures 
were moderately correlated. Correlation coefficients 
were: referral ratio versus detection rate (0.42), referral 
ratio versus conversion rate (−0.35), and detection rate 
versus conversion rate (0.37). The table shows the anal-
ysis of all cause mortality in relation to referral ratio, 
conversion rate, and detection rate. Each distribution 
was divided by tertiles (that is, in three equal groups). 
Referral ratio was associated with mortality, with haz-
ard ratios of 1.05 (95% confidence interval 1.04 to 1.07) 
in the lowest group and 0.97 (0.96 to 0.99) in the highest 
group, each compared with the intermediate group. 
Detection rate was also associated with mortality, with 
hazard ratios of 1.04 (1.02 to 1.06) in the lowest group 
and 0.96 (0.95 to 0.98) in the highest group. Conversion 
rate was not associated with mortality.
The web figure shows the analyses based on groups 
divided by deciles of the distributions of referral ratio, 
conversion rate, and detection rate (that is, divided into 
10 equal groups). Mortality decreased with the level of 
referral ratio and detection rate. There was no sugges-
tion of attenuation of the effects of referral ratio and 
detection rate towards the highest groups. We saw no 
suggestion of an association with conversion rate, even 
at the lowest or highest groups.
Figure 3 shows the detailed analysis of joint effects of 
referral ratio and detection rate on mortality, with each 
measure divided into three equal groups. There are nine 
combinations in this 3×3 classification, and we used the 
intermediate groups of the two variables as the refer-
ence category in the Cox regression analysis. A low haz-
ard ratio was seen for the combination of high referral 
ratio and high detection rate (0.96 (95% confidence 
interval 0.94 to 0.99); hereafter referred to as group 1 of 
the study population). High hazard ratios were seen for 
combinations of low referral ratio and low detection 
rate, or if one variable was low and the other was 
 intermediate. The corresponding hazard ratios for these 
combinations were 1.08 (1.06 to 1.11), 1.07 (1.04 to 1.10), 
and 1.05 (1.02 to 1.08); we refer to this segment of the 
study population as group 3. Group 2 refers to the 
remaining study population.
Figure 3 shows combinations of referral ratio and 
detection rate with similar hazard ratios. Group 1 (the 
bottom right section of figure 3) comprised 16% 
(n=34 758) of the study population with a high referral 
ratio and high detection rate (hazard ratio 0.96 (95% 
confidence interval 0.94 to 0.98), and group 3 (the top 
left section of figure 3) comprised 37% (n=79 416) of the 
study population with a low or low/intermediate refer-
ral ratio and detection rate (1.07 (1.05 to 1.08)). These 
groups were compared with group 2, which comprised 
47% (n=101 110) of the study population, had other 
combinations of referral ratio and detection rate, and 
had hazard ratios close to 1. 
To give illustrate the absolute magnitude of the 
observed differences, we derived the cumulative mortal-
ity at four years from the Cox regression models. The 
extreme difference between patient groups in the 3×3 
classification in figure 3 was a 6% point difference in 
four year survival, with the hazard ratios of 1.08 and 0.96 
corresponding to cumulative mortality risks of 53% and 
47%, respectively. For the three derived groups (with 
hazard ratios of 1.07, 1.00, and 0.96, respectively) the cor-
responding cumulative risks were 52%, 49%, and 47%. 
The 3% point difference in four year cumulative mortal-
ity between group 3 (corresponding to a low use of 
Tumour records from Meechan and colleagues18 (n=224 984)
Records from patients with cancer
included in analysis (n=215 284)
Excluded (n=9700):
  Multiple records (n=5276)
  Records with no cancer registration (n=4374)
  Records with invalid data for conversion rate
    or detection rate (n=50)
Fig 1 | Flow diagram of study population with inclusions and 
exclusions
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Fig 2 | Histograms of referral ratio, conversion rate, and 
detection rate
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urgent referral) and group 2 (corresponding to the more 
common, higher use of urgent referral) applies to almost 
80 000 patients in group 3. This difference suggests that 
an additional 2400 patients with cancer in group 3 might 
have been alive at the four year time point if the use of 
urgent referral had been higher, as in group 2.
The web appendix shows stratified analyses and sen-
sitivity analyses of the three groups identified from fig-
ure 3. The general pattern was observed consistently for 
the main cancer types, with the exception of female 
breast cancer, which had no association with mortality 
across the three groups. Exclusion of breast cancer from 
the overall analysis did not change the general result. 
Compared to the overall analysis with up to four years 
of follow-up, there were slightly stronger mortality 
effects in the first year of follow-up. 
The overall results did not change materially when 
adjusted for the patient’s socioeconomic status, or 
restricted to the subset of patients for whom the diagno-
sis and date of diagnosis were consistent with the can-
cer registry. Results remained unchanged after we made 
no adjustment for type of cancer, or with additional 
adjustment for characteristics of the general practice 
list  population. Furthermore, we fitted a random effects 
model to accommodate the multilevel structure of data 
according to groups of patients with cancer belonging 
to each practice list, which made no effect on the over-
all results.
discussion
Principal findings
This analysis of the mortality of more than 200 000 
patients with cancer in England shows that the propen-
sity of general practices to use the urgent referral path-
way for suspected cancer was associated with the 
mortality outcome of their patients. Their accuracy in 
case selection for urgent referral (conversion rate), 
however, was not associated with mortality. Referral 
ratio and detection rate are both measures of a general 
practice’s propensity to use the urgent referral pathway, 
and both were independently associated with mortality. 
The hazard of death was 4% lower for the 16% of 
patients from practices with high use and 7% higher for 
the 37% of patients from practices with low use, com-
pared with the 47% of all patients from practices with 
intermediate use.
interpretation and comparison with other research
The association between use of the urgent referral path-
way and mortality is consistent for the main types of can-
cer except breast cancer and not sensitive to details of 
inclusion or exclusion of patient subgroups or to the 
details of the statistical model of analysis. Thus, there is 
most plausibly an underpinning principle or mechanism 
of a general nature, although the possibility of bias from 
unknown confounding variables cannot be ruled out.
The associations with mortality were stronger in the 
first year after diagnosis, which may point to a role of 
cancer stage in the underlying mechanism. A reduction 
in diagnostic interval could contribute towards lower 
mortality through a more favourable stage distribution 
and better treatment options.
One important finding was that the conversion rate 
was not associated with mortality. Based on extensive 
research on the positive predictive values of symptoms 
that may suggest cancer in general practice,29 30 there is 
Low detection rate Intermediate detection rate High detection rate
37 982
16 539
1.08 (1.06 to 1.11)
Low
referral
ratio
20 852
9193
1.07 (1.04 to 1.10)
12 939
5404
1.01 (0.97 to 1.04)
20 582
8912
1.05 (1.02 to 1.08)
Intermediate
referral
ratio
27 468
11 465
1.00
23 718
10 040
1.00 (0.97 to 1.02)
13 240
5621
1.02 (0.99 to 1.05)
High
referral
ratio
23 745
10 091
1.00 (0.97 to 1.03)
34 758
14 355
0.96 (0.94 to 0.99)
Group 3 Group 1Group 2
Fig 3 | Hazard ratios for death in two way classification of referral ratio and detection rate. 
Data are numbers of people and deaths, and adjusted hazard ratios for death with 95% 
confidence intervals
Hazard ratios for death in relation to referral ratio, conversion rate, and detection rate
variable and 
group median value lowest value Highest value no of people no of deaths Hazard ratio (95% Ci)* Hazard ratio (95% Ci)†
referral  ratio
Low 0.68 0.20 0.86 71 773 31 136 1.05 (1.04 to 1.07) 1.04 (1.02 to 1.06)
Intermediate 1.01 0.86 1.16 71 768 30 417 1.00 1.00
High 1.39 1.16 3.44 71 743 30 067 0.97 (0.96 to 0.99) 0.98 (0.97 to 1.00)
Ptrend — — — — — <0.001 <0.001
Conversion rate
Low 0.08 0.00 0.10 71 811 30 206 1.00 (0.99 to 1.02) 1.00 (0.98 to 1.02)
Intermediate 0.12 0.10 0.14 72 101 30 672 1.00 1.00
High 0.17 0.14 1.00 71 372 30 742 1.01 (1.00 to 1.03) 1.00 (0.98 to 1.02)
Ptrend — — — — — 0.117 0.748
Detection rate
Low 0.33 0.00 0.39 71 804 31 072 1.04 (1.02 to 1.06) 1.03 (1.01 to 1.05)
Intermediate 0.43 0.39 0.48 72 065 30 749 1.00 1.00
High 0.54 0.48 1.00 71 415 29 799 0.96 (0.95 to 0.98) 0.97 (0.95 to 0.99)
Ptrend — — — — — <0.001 <0.001
*Adjusted for age, sex, and cancer type.
†Adjusted for age, sex, and cancer type; and mutually adjusted.
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a prevailing assumption that a high conversion rate is a 
consequence of general practitioners referring mainly 
when the patient has developed alarm symptoms for 
cancer. In turn, this point of referral is associated with 
higher mortality rates for their patients. The lack of 
association in the present analysis could reflect the 
clinical assessment made by the general practitioner 
when deciding on referral. Referral decisions involve a 
multifactorial process, taking account of a patient’s 
demographic features, medical history, help seeking 
behaviour, and preferences, rather than simply 
responding to symptoms of possible cancer and relating 
these to guidelines. The observed effect of urgent refer-
ral could therefore reflect general practitioners’ cancer 
awareness and willingness to use the urgent referral 
pathway for suspected cancer rather than the adher-
ence to specific symptom based guidelines.
Indirect effects should be considered in this observa-
tional study, such as the possible effect of the lead time 
of earlier diagnoses on estimated mortality hazard 
ratios.31 An earlier diagnosis would inevitably reduce 
estimated death rates of patients with cancer, even 
without any effect on stage distribution or prognosis.
There could be other factors associated with general 
practices with a high referral ratio and high detection 
rate that account for the observed lower mortality. For 
example, general practitioners in practices with older 
patients could be more aware of cancer and more famil-
iar with the urgent referral pathway. This might contrib-
ute to the finding in sensitivity analyses of an association 
between the age composition of the practice population 
and the mortality of patients with cancer (that is, higher 
age is associated with lower mortality), independent of 
the effect of referral ratio and detection rate.
In a study32 using data from 2012 on referral and can-
cer stage, higher use of urgent referral of patients with 
suspected cancer was associated with a reduced propor-
tion of patients with advanced cancer. The study had 
insufficient follow-up time to consider the survival out-
come, but it supports our interpretation that high use of 
the urgent referral pathway could operate through a 
stage mediated mechanism, as opposed to a lead time 
effect. It remains a weakness of our data that stage was 
poorly recorded in 2009. Since the modernisation of the 
English cancer registry, the recording of stage has been 
much improved and we will be able to analyse the medi-
ation effect of stage on survival when the 2012 data has 
accrued a few more years of follow-up for death.
Other potential indirect mechanisms are that where 
general practitioners have better access to pre-referral 
tests, they may use these tests more frequently in 
patients with suspicious symptoms, identifying those 
with cancer earlier while also being more accurate in 
their case selection for urgent referral. Variation in the 
quality of clinical care could mean that patients receiv-
ing less good quality care could have diagnoses later, 
more frequently after emergency presentation, and 
have worse outcomes. Furthermore, our analyses 
assume that specialist service provision and treatment 
decision making is comparable for patients of all prac-
tices. Although national guidance has existed for some 
time on the specialist diagnosis and management of 
individual cancers, a degree of variation in clinical 
practice of individual specialists is inevitable.
In breast cancer, there was no association with referral 
ratio or detection rate, which is a departure from the over-
all pattern. The availability of the organised mam-
mographic screening programme could result in many 
patients with early stage (and therefore good prognosis) 
breast cancer being detected through screening and not 
through the urgent referral pathway. We attempted to 
explore this idea by analysing cervical cancer, where an 
organised screening programme also exists, but the num-
bers of deaths were low and the results not conclusive. In 
the English urgent referral system, the inclusion criteria 
have been extended to ensure that women with breast 
symptoms who do not meet the clinical criteria for sus-
pected cancer are still seen within two weeks. For patients 
with breast cancer, this would reduce the differences 
between general practices’ low and high referral ratios.
Strengths and limitations of the study
The analysis was based on the complete national popu-
lation of England, using nearly complete Cancer Wait-
ing Times records from hospitals and cancer incidence 
and death records from population based cancer regis-
tration. The analysis strategy aimed to create the same 
result as that from an intention to treat analysis of a 
controlled trial of urgent referral. We included all 
patients with cancer in the mortality analysis and 
hereby eliminated some known biases and artefacts 
that arise from two things:
•	 A comparison of patients with cancer with short and 
long time to treatment (the waiting times paradox,33 
where short delay has been associated with poor 
prognosis through reverse causation)
•	 Comparison of urgently and non-urgently referred 
patients, subject to selection bias and confounding by 
indication, and often with different results for different 
types of cancer and different red flag symptoms.34 35 
If urgent referral was reserved only for those patients 
presenting alarming symptoms that might indicate 
advanced cancer stage, a higher use of urgent referral 
could be biased towards a less favourable outcome 
(increased mortality). Nevertheless, we were able to 
demonstrate the opposite result of lower mortality asso-
ciated with higher use of urgent referral.
By its design, the present analysis attempted to deter-
mine whether there is a mortality difference between a 
situation where an urgent referral route exists and is 
being used and another situation where such a mecha-
nism does not exist or is not being used. Because the 
effects on mortality were estimated by time to event, 
there would be a contribution of lead time to the observed 
effect on mortality. We were not able to correct for this, or 
estimate the contribution of lead time from these data. 
Based on data from the UK General Practice Research 
Database, it was found that the introduction of guide-
lines for urgent referral from the National Institute for 
Health and Care Excellence in 2005 led to an average 
reduction in diagnostic interval of 5.4 days.36 A lead time 
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of this magnitude is not likely to fully explain the 
observed mortality differences in the present analysis. 
However, the present analysis was able to look at the 
most likely causes of possible case mix variation between 
the groups of general practices (age, sex, types of cancer, 
and socioeconomic group), but as in any observational 
study, there remains, in principle, the possibility of bias 
from unknown confounding variables.
At the level of an individual practice, the measured 
characteristics (referral ratio, conversion rate, and detec-
tion rate) are often based on small numbers of referrals 
and cancer cases, and it should be appreciated that the 
measurements are inherently variable, including year on 
year random variation and cancer case mix.21  We advise 
against over-interpretation of these results at the level of 
the individual general practitioner or practice in a single 
year, but we believe that the identified patterns—based 
on aggregate groups of general practices and their 
patient populations—contain relevant and important 
information. As a consequence of the inherent variability 
of these measurements, the magnitude of the estimated 
mortality effect is likely to be under-estimated through 
non-differential misclassification. The joint effect of 
referral ratio and detection rate, where these are consis-
tent (that is, both are low or both are high), is a repeated 
measurements situation that may identify general prac-
tices more accurately with a truly low or a truly high pro-
pensity to use urgent referral.37
In the present analysis, we calculated the referral 
ratio, conversion rate, and detection rate in a single 
year’s activity and for all cancers combined. Although we 
found consistent results for the main types of cancer 
(except breast cancer) and the results were not sensitive 
to the adjustment for cancer type, cancer awareness and 
choice of referral mechanism might not be the same for 
all cancer types and their symptoms. A more focused 
analysis could start with characteristics of urgent referral 
computed separately for each of the main types of can-
cer. This would require analysis based on several years of 
data and also, optimally, information on symptoms.
Questions arising from this study
The analysis and interpretation of the results have led 
us to define new questions for future studies. Firstly, it 
should be established whether the general association 
between use of urgent referral and mortality of patients 
with cancer can be replicated in a more recent period, 
and in other national populations with comparable 
referral pathways. Secondly, it is necessary to under-
stand how stable practice referral and detection rates 
are, year on year. Thirdly, the characteristics of prac-
tices with low referral and detection rates merit further 
study. If these measures are associated more generally 
with other measures of practice performance, interven-
tions and education could be more targeted. Fourthly, 
the health economic consequences of modifying the 
practice referral ratio need to be elaborated. For some 
practices, the use of urgent referral might be too low 
and increased use in the group of general practices with 
both low referral ratio and low detection rate could lead 
to further improvement in cancer survival. 
We are aware that the increased use of urgent referral 
could be costly in terms of diagnostic and clinical resource, 
and consider that the cost effectiveness of increasing activ-
ity within the urgent referral pathway for suspected cancer 
should be explored in detail. Since 2009, the use of urgent 
referral in England has increased by more than 50% to 
over 1.2 million referrals per year.38  Updated NICE guid-
ance on urgent referral for suspected cancer lowers the 
threshold for referral,12 39  and has been modelled to poten-
tially increase referrals to two million per year.40 To ensure 
the most rational use of urgent referral, its use must be 
based on sound clinical research conducted in general 
practice and take account of available guidelines. We 
should continue to monitor the variability in the use of this 
referral pathway and its association with mortality.
Conclusion and implications
In this analysis, we have found a clinically relevant asso-
ciation between the low use of urgent referral for sus-
pected cancer in general practices and increased risk of 
death among patients with cancer. The conversion rate 
of urgent referrals to cancer diagnoses was not associ-
ated with mortality. This lack of association suggests 
that the general practitioners’ cancer awareness and 
willingness to use the urgent referral pathway, together 
with the complete clinical assessment, could produce a 
positive effect of urgent referral for suspected cancer.
We have identified a subgroup of 37% of patients with 
cancer who were registered in 2009 with general prac-
tices with a low propensity to use urgent referral. Patients 
in these practices had a 7% increased mortality rate com-
pared with those from practices with higher rates of 
urgent referral. For practices that have a consistently low 
propensity to use the urgent referral pathway (for exam-
ple, on measures and in consecutive years), the data sug-
gest that an increased use could plausibly lead to lower 
mortality and higher survival of patients with cancer.
The absolute differences in cumulative mortality are 
around 5% or 6% points in the risk of death within four 
years after the cancer diagnosis. This difference 
approaches the magnitude of known and important differ-
ences in survival between England and comparable coun-
tries41  or between socioeconomic groups within England.42
The English national Cancer Waiting Times database was obtained 
from NHS England, containing data from the National Cancer Waiting 
Times Monitoring Dataset.
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Web appendix: Analysis of the three main cancer 
patient groups identified in figure 3 on the basis of GP 
urgent referral characteristics. Stratified analyses by 
cancer type and sensitivity analyses with different 
durations of follow-up, inclusion criteria and 
regression model specification
Web figure: HRs for death in relation to referral ratio, 
conversion rate and detection rate deciles, adjusted for 
age, sex and cancer type, and mutually adjusted
A. Overall analysis (215,284 patients; 91,620 deaths) H. Follow‐up time limited to 0‐1 year after diagnosis
Group* Patients % Deaths HR 95% CI Group Patients % Deaths HR 95% CI
1 34,758 16 14,355 0.96 0.94 0.98 1 34,758 16 7,842 0.94 0.92 0.97
2 101,110 47 42,621 1.00 2 101,110 47 23,764 1.00
3 79,416 37 34,644 1.07 1.05 1.08 3 79,416 37 20,000 1.09 1.07 1.11
p‐trend <0.001 p‐trend <0.001
B. Restricted to colorectal cancer I. Follow‐up time limited to 0‐2 year after diagnosis
Group Patients % Deaths HR 95% CI Group Patients % Deaths HR 95% CI
1 3,865 16 1,670 0.97 0.92 1.02 1 34,758 16 11,020 0.96 0.94 0.98
2 11,611 47 5,175 1.00 2 101,110 47 32,867 1.00
3 9,160 37 4,145 1.03 0.99 1.08 3 79,416 37 27,146 1.08 1.06 1.09
p‐trend 0.017 p‐trend <0.001
C. Restricted to lung cancer J. Also adjusted for the patient's socioeconomic status**
Group Patients % Deaths HR 95% CI Group Patients % Deaths HR 95% CI
1 3,596 16 3,107 0.96 0.93 1.00 1 34,758 16 14,355 0.96 0.94 0.98
2 10,411 46 9,086 1.00 2 101,110 47 42,621 1.00
3 8,779 39 7,743 1.05 1.02 1.08 3 79,416 37 34,644 1.06 1.05 1.08
p‐trend <0.001 p‐trend <0.001
D. Restricted to female breast cancer K. Diagnosis and length of follow‐up consistent with cancer register
Group Patients % Deaths HR 95% CI Group Patients % Deaths HR 95% CI
1 5,108 15 997 1.05 0.98 1.13 1 27,112 16 10,913 0.95 0.93 0.98
2 15,964 48 2,872 1.00 2 78,371 47 32,258 1.00
3 12,497 37 2,172 1.03 0.97 1.09 3 60,664 37 25,795 1.06 1.05 1.08
p‐trend 0.842 p‐trend <0.001
E. Restricted to prostate cancer L. Not adjusted for type of cancer
Group Patients % Deaths HR 95% CI Group Patients % Deaths HR 95% CI
1 4,325 17 984 0.95 0.88 1.02 1 34,758 16 14,355 0.97 0.95 0.99
2 12,033 47 2,826 1.00 2 101,110 47 42,621 1.00
3 9,297 36 2,239 1.07 1.01 1.13 3 79,416 37 34,644 1.08 1.06 1.09
p‐trend 0.001 p‐trend <0.001
F. Restricted to cancers other than colorectal, lung, breast, prostate. M. Also adjusted for GP population age and sex distribution***
Group Patients % Deaths HR 95% CI Group Patients % Deaths HR 95% CI
1 17,827 16 7,581 0.94 0.92 0.97 1 34,758 16 14,355 0.97 0.95 0.99
2 50,976 47 22,632 1.00 2 101,110 47 42,621 1.00
3 39,601 37 18,324 1.09 1.07 1.11 3 79,416 37 34,644 1.05 1.04 1.07
p‐trend <0.001 p‐trend <0.001
G. All cancers excluding female breast cancer N. Shared frailty model for prostate cancer (GP as random effect)
Group Patients % Deaths HR 95% CI Group Patients % Deaths HR 95% CI
1 29,650 16 13,358 0.95 0.93 0.97 1 4,325 17 984 0.95 0.88 1.02
2 85,146 47 39,749 1.00 2 12,033 47 2,826 1.00
3 66,919 37 32,472 1.07 1.05 1.09 3 9,297 36 2,239 1.07 1.01 1.13
p‐trend <0.001 p‐trend 0.001
*Group 1: High referral ratio and high detection rate. **From J: Most vs. least deprived quintile:
Group 2: All other combinations than group 1 and group 3. HR: 1.34 (1.32‐1.37); p‐trend over quintiles <0.001
Group 3: Low or low/intermediate referral ratio and detection rate 141 records with missing value for SES included as a separate category
Hazard ratios adjusted for age, sex and cancer type.
***From M: Effects of GP population characteristics:
HR: 0.88 (0.86‐0.90) for highest vs. lowest tertile of median age
HR: 1.13 (1.08‐1.17) per 10 percentage point increase in male proportion
Appendix. Analysis of the three main cancer patient groups identified in Figure 3 on the basis of GP urgent referral characteristics. Stratified analyses by cancer type and sensitivity 
analyses with different durations of follow‐up, inclusion criteria and regression model specifications.
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